Vascular calcification in chronic kidney failure: role of vitamin D receptor

J Ruth Wu-Wong1, Joel Melnick

  • 1Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064, USA. ruth.r.wuwong@abbott.com

Current Opinion in Investigational Drugs (London, England : 2000)
|April 6, 2007
PubMed

Insights

Vitamin D receptor activator (VDRA) therapy offers survival benefits for chronic kidney disease (CKD) patients, despite concerns about vascular calcification. Different VDRAs may differentially impact CKD-related cardiovascular risks.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Endocrinology

Background:

  • Chronic kidney disease (CKD) patients face higher cardiovascular disease and mortality risks, linked to atherosclerosis and vascular calcification.
  • Vascular calcification is a regulated process involving an imbalance of inducing and inhibitory factors, with specific factors remaining unidentified.
  • The vitamin D receptor (VDR) is a nuclear receptor, and its activators (VDRAs) like paricalcitol and calcitriol treat secondary hyperparathyroidism in CKD.

Purpose of the Study:

  • To investigate the role of VDRAs in vascular calcification within CKD patients.
  • To reconcile the observed survival benefits of VDRA therapy with potential pro-calcification effects.
  • To explore differential effects of VDRAs on endocrine versus paracrine/autocrine VDR pathways.

Main Methods:

  • Literature review of existing studies on VDRA therapy and vascular calcification in CKD.
  • Analysis of clinical observations regarding VDRA therapy and patient survival, independent of mineral levels.
  • Examination of potential mechanisms by which VDRAs might influence vascular health.

Main Results:

  • Clinical data indicate a survival benefit order for VDRA therapy: paricalcitol > calcitriol > no VDRA.
  • This survival benefit exists independently of serum parathyroid hormone, phosphorus, and calcium levels.
  • Current literature presents inconsistent findings on the impact of VDRAs on vascular calcification.

Conclusions:

  • VDRA therapy demonstrates a survival advantage in CKD patients.
  • The seemingly contradictory effects of VDRAs on survival and potential calcification warrant further investigation.
  • Differential effects of various VDRAs on VDR signaling pathways may explain observed clinical outcomes.

Related Concept Videos

Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Skeleton and Calcium Homeostasis01:21

Skeleton and Calcium Homeostasis

Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.
Role of Skin in Vitamin D Synthesis01:23

Role of Skin in Vitamin D Synthesis

The skin plays a crucial role in the synthesis of vitamin D, a vital nutrient for various physiological processes in the body. Vitamin D is unique because it can be synthesized in the skin through a series of chemical reactions triggered by exposure to ultraviolet B (UVB) radiation from sunlight.
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin D3(cholecalciferol).
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...